Oncology

Alimta

Build a treatment strategy from survival with ALIMTA. Discover why ALIMTA is the foundational therapy for thoracic cancers. Learn more about ALIMTA/cisplatin for the treatment of first line advanced NSCLC with nonsquamous* cell histology.
*Adenocarcinoma, large cell carcinoma, and other histologies. Learn more

Gemzar

Gemcitabine is indicated for the treatment of locally advanced or metastatic bladder cancer in combination with cisplatin.Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas.
Gemcitabine, in combination with cisplatin is indicated as first line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.
Gemcitabine is indicated for the treatment of patients with locally advanced or metastatic epithelial ovarian carcinoma, in combination with carboplatin, in patients with relapsed disease following a recurrence-free interval of at least 6 months after platinum-based, first-line therapy.
Gemcitabine, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated. Learn more

Top
TGlsbHkwMS0wNjIwMTY=